LUNA Technologies Spółka z Ograniczoną Odpowiedzialnością (KRS 0000709669, NIP 8863001914) is a Polish company, headquartered in Wrocław, Dolnośląskie voivodeship. LUNA TECHNOLOGIES operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since December 21, 2017. LUNA TECHNOLOGIES's operations are currently suspended.
The company is currently suspended
Suspended since December 11, 2025
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - LUNA Technologies
Identity
- Name
- LUNA Technologies Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- December 21, 2017
- Registry status as of
- April 22, 2026
- Latest entry
- April 22, 2026
- Founding act
- 15.09.2017R., NOTARIUSZ ANNA SZERER, KANCELARIA NOTARIALNA W WAŁBRZYCHU UL. SŁOWACKIEGO 16, REPERTORIUM A NR 4270/2017
Articles of association history (5)
- September 15, 2017: 15.09.2017R., NOTARIUSZ ANNA SZERER, KANCELARIA NOTARIALNA W WAŁBRZYCHU UL. SŁOWACKIEGO 16, REPERTORIUM A NR 4270/2017
- September 14, 2018: 14.09.2018 R., NOTARIUSZ DR RAFAŁ FIRLEJ Z KANCELARII NOTARIALNEJ W WAŁBRZYCHU, UL. SŁOWACKIEGO 13/3, REP. A NR 8329/2018, ZMIENIA SIĘ § 2, § 3, § 6, § 7, § 12, UCHYLA SIĘ TREŚĆ § 21, § 22 OTRZYMUJE NR 21 A § 23 OTRZYMUJE NR 22.
- July 3, 2019: 03.07.2019 R., NOTARIUSZ JÓZEF OGIELSKI, KANCELARIA NOTARIALNA WALDEMAR GRYBOŚ I JÓZEF OGIELSKI SPÓŁKA CYWILNA PRZY UL. WITA STWOSZA 1-2 WE WROCŁAWIU, REPERTORIUM A NR 5696/2019 - ZMIENIONO: § 2, § 3, § 6 I § 16 UMOWY SPÓŁKI. 03.09.2019 R., NOTARIUSZ JÓZEF OGIELSKI, KANCELARIA NOTARIALNA WALDEMAR GRYBOŚ I JÓZEF OGIELSKI SPÓŁKA CYWILNA PRZY UL. WITA STWOSZA 1-2 WE WROCŁAWIU, REPERTORIUM A NR 7533/2019 - ZMIENIONO: § 2 UMOWY SPÓŁKI.
- August 13, 2021: 13.08.2021, REP. A NR 9025/2021, NOTARIUSZ JÓZEF OGIELSKI, KANCELARIA NOTARIALNA WE WROCŁAWIU, UCHYLONO DOTYCHCZASOWY TEKST UMOWY SPÓŁKI I UCHWALONO NOWY TEKST UMOWY SPÓŁKI.
- April 20, 2022: 20.04.2022R.,NOTARIUSZ JÓZEF OGIELSKI, KANCELARIA NOTARIALNA WE WROCŁAWIU, REPERTORIUM A NR 6130/2022 - ZMIENIONO: §2, §6, §7, §14 UMOWY SPÓŁKI. PRZYJĘTO TEKST JEDNOLITY UMOWY SPÓŁKI.
Activities
Main activity
72.19.ZOther research and experimental development on natural sciences and engineering
Other activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. MARSZAŁKA EDWARDA RYDZA-ŚMIGŁEGO, 15, 52-213, WROCŁAW, POLSKA
- Voivodeship
- DOLNOŚLĄSKIE
- District
- WROCŁAW
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-30824-52961-CSAJD-25
Operational status - LUNA Technologies
Founded
December 21, 2017
8 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
WROCŁAW
DOLNOŚLĄSKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
8.0 K PLN
160 shares total
Shareholders
3
shareholders
Board
1 person
Filed years
N/A
Registry entries
31
latest: April 22, 2026
Risk signals
No KPI data - financial statements and valuation are unavailable for this company.
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - LUNA Technologies.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
